Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CAI:PHAR's Return-on-Tangible-Asset is ranked better than 64.65% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.99
vs CAI:PHAR: 6.07
Egyptian International Pharmaceutical Investments (CAI:PHAR) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Egyptian International Pharmaceutical Investments Return-on-Tangible-Asset Related Terms
Egyptian International Pharmaceutical Investments Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments Return-on-Tangible-Asset Chart
Egyptian International Pharmaceutical Investments Annual Data
CAI:PHAR vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egyptian International Pharmaceutical Investments Return-on-Tangible-Asset vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 6.36% mean?
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a Return-on-Tangible-Asset of 6.36% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Egyptian International Pharmaceutical Investments and its competitors. This is 51% below median its historical median of 12.92. Over the past decade, Egyptian International Pharmaceutical Investments' Return-on-Tangible-Asset has ranged from 6.07 to 22.74. According to the industry distribution chart, Egyptian International Pharmaceutical Investments ranks #356 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 35.4%.
Is Egyptian International Pharmaceutical Investments' Return-on-Tangible-Asset too high?
Egyptian International Pharmaceutical Investments' current Return-on-Tangible-Asset of 6.36% is 51% below median its 10-year median of 12.92. Over the past 10 years, this metric has ranged from a low of 6.07 to a high of 22.74. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.99. Egyptian International Pharmaceutical Investments' value of 6.36% is 112.7% above this industry median. Based on the distribution chart, Egyptian International Pharmaceutical Investments ranks #356 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Egyptian International Pharmaceutical Investments ranks #356 out of 1007 companies for Return-on-Tangible-Asset. This puts Egyptian International Pharmaceutical Investments in the upper half of its industry. The industry median Return-on-Tangible-Asset is 2.99. Egyptian International Pharmaceutical Investments' value of 6.36% is 112.7% above this benchmark. Historically, Egyptian International Pharmaceutical Investments' own Return-on-Tangible-Asset has ranged from 6.07 to 22.74 over the past decade. While the company's 10-year median is 12.92 vs. the industry median of 2.99, Egyptian International Pharmaceutical Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.99, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egyptian International Pharmaceutical Investments's current Return-on-Tangible-Asset of 6.36% is 112.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Egyptian International Pharmaceutical Investments and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egyptian International Pharmaceutical Investments's current Return-on-Tangible-Asset is 6.36%, which is 51% below median its own 10-year median of 12.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£67.53, compared to a current price of E£153.55 — trading 127.4% above its estimated fair value. The current Return-on-Tangible-Asset is 6.36%, which is 51% below median its 10-year median of 12.92 and 112.7% above the Drug Manufacturers industry median of 2.99. Egyptian International Pharmaceutical Investments' overall GF Score™ is 63/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current Return-on-Tangible-Asset is 6.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued.
The current stock price of E£153.55 is trading 127.4% above its estimated GF Value™ of E£67.53.
GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.
Key valuation signals for CAI:PHAR:
Return-on-Tangible-Asset: 6.36% (51% below median its 10-year median of 12.92)
GF Value™: E£67.53 vs. price of E£153.55 (127.4% above fair value)
Industry Position: 112.7% above the Drug Manufacturers median (#356 of 1007)
No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
63GF Score
Get the complete analysis for CAI:PHAR
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:PHAR has been successfully added to your 
